Cortical thickness in chronic pain
A protocol for systematic review and meta-analysis

HaiRong Ma, MD\textsuperscript{a}, LiQin Sheng, MD\textsuperscript{a}, Fei Chen, MD\textsuperscript{b}, CongHu Yuan, MD\textsuperscript{c}, ZhenYu Dai, MD\textsuperscript{b}, PingLei Pan, MD\textsuperscript{d,e,∗}

Abstract

Background: Numerous studies using a variety of non-invasive neuroimaging techniques in vivo have demonstrated that chronic pain (CP) is associated with brain alterations. Cortical thickness (CTh) via surface-based morphometry (SBM) analysis of magnetic resonance imaging data is a valid and sensitive method to investigate the structure of brain gray matter. Many studies have employed SBM to measure CTh difference between patients with CP and pain-free controls and provided important insights into the brain basis of CP. However, the findings from these studies were inconsistent and have not been quantitatively reviewed.

Methods: Three major electronic medical databases: PubMed, Web of Science, and Embase were searched for eligible studies published in English on April 3, 2020. This protocol was prepared based on the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols. The Seed-based d Mapping with Permutation of Subject Images software package will be employed to conducted a coordinate-based meta-analysis (CBMA) to identify consistent CTh differences between patients with CP and pain-free controls. Several complementary analyses, including sensitivity analysis, heterogeneity analysis, publication bias, subgroup analysis, and meta-regression analysis, will be further conducted to test the robustness of the results.

Results: This CBMA will tell us whether CP with different subtypes shares common CTh alterations and what the pattern of its characterized alterations is.

Conclusions: To the best of our knowledge, this will be the first CBMA of SBM studies that characterizes brain CTh alterations in CP. The CBMA will provide the quantitative evidence of common brain cortical morphometry of CP. The findings will help us to understand the neural basis underlying CP.

Trial Registration number: INPLASY202050069

Abbreviations: CBMA = coordinate-based meta-analysis, CP = chronic pain, CTh = cortical thickness, FWE = family-wise error, GM = gray matter, HC = healthy control, MNI = Montreal Neurological Institute, MRI = magnetic resonance imaging, PRISMA-P = Preferred Reporting Items for Systematic review and Meta-Analysis Protocols, SBM = surface-based morphometry, SDM-PSI = Seed-based d Mapping with Permutation of Subject Images, TFCE = threshold-free cluster enhancement, TR/TE = repetition time/echo time, VBM = voxel-based morphometry.

Keywords: chronic pain, coordinate-based meta-analysis, cortical thickness, gray matter, seed-based d mapping with permutation of subject images

1. Introduction

Chronic pain (CP) is defined as pain that persists or recurs for more than 3 months.\textsuperscript{1,2} CP is highly prevalent worldwide and has emerged as a major global public health.\textsuperscript{3,4} CP adversely affects a person’s physical function and quality of life and causes a substantial societal economic burden.\textsuperscript{5,6} Although CP is heterogeneous in forms and in etiologies; there is convergent evidence that CP may share a common pathophysiology associated with central nervous system reorganizations. Numerous studies using a variety of non-invasive neuroimaging techniques in vivo have demonstrated CP-related brain alterations in the neurochemical profile, regional gray matter (GM), regional spontaneous activity, functional connectivity and networks.\textsuperscript{7–16} The key altered brain areas, including the sensorimotor, prefrontal, cingulate, and insular cortices in the sensorimotor network, default mode network, and salience network, were not only involved in sensory processing, but also in cognitive-affective processing, which have helped us to understand the maladaptive neurobiological mechanisms leading to the development of CP.\textsuperscript{17}
magnetic resonance imaging (MRI) data is a valid method to study the structure of brain GM. Compared to voxel-based morphometry (VBM) that provides a mixed measure of GM including cortical surface area or cortical folding as well as cortical thickness, SBM may be more sensitive to detect subtle brain structural differences between groups. VBM and SBM are complementary methods for the observation of brain morphometry. Several meta-analyses of VBM and SBM are complementary methods for the observation of CP. Studies have shown consistent evidence of GM volume/density and cortical thickness, SBM may be more sensitive to detect subtle brain structural differences between patients with CP and pain-free controls and provided important insights into the brain basis of CP. However, the findings from these studies were inconsistent and have not been quantitatively reviewed. It remains unknown whether CP with different subtypes shares common CTh alterations and what the pattern of its characterized alterations is. For this purpose, meta-analysis is essential for the synthesis of the findings from these CTh studies.

Coordinate-based meta-analysis (CBMA) is a useful technique to detect consistency of brain alterations across neuroimaging studies in a particular disorder for a specific question. In the present study, we will use Seed-based d Mapping with Permutation of Subject Images (SDM-PSI) to perform this CBMA of CTh studies in CP.

2. Methods

2.1. Literature search strategies

Three major electronic medical databases: PubMed, Web of Science, and Embase were searched for eligible studies published in English from each database’s inception to April 3, 2020. The following terms were used for the searches: ((chronic pain) OR (chronic myofascial pain) OR (chronic headache) OR (chronic migraine) OR (burning mouth syndrome) OR (temporomandibular joint disorder) OR (neck pain) OR (shoulder pain) OR (phantom limb pain) OR (chronic thoracic pain) OR (chronic chest pain) OR (chronic back pain) OR (chronic knee pain) OR (chronic ankle pain) OR (chronic epicondylalgia) OR (chronic abdominal pain) OR (chronic visceral pain) OR (chronic pelvic pain syndrome) OR (neuropathic pain) OR (trigeminal neuralgia) OR neuralgia OR (postherpetic neuralgia) OR (chronic widespread pain) OR (chronic whiplash-associated disorder) OR arthritis OR (somatoform pain) AND ((cortical thickness) OR (cortical thinning) OR (surface-based morphometry)). Neither article language nor publication time was limited. In addition, manual searches were conducted within the reference lists of the included studies and any relevant review articles.

This protocol was prepared based on the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P).

2.2. Eligibility criteria

2.2.1. Inclusion criteria. The studies have to meet the following inclusion criteria:

1. studies that investigated regional CTh differences between patients with CP and matched pain-free controls at the whole-brain cortical level;
2. studies with non-significant results and studies with significant findings that reported brain clusters in standard Montreal Neurological Institute (MNI) or Talairach space;
3. an original article published in English in a peer-reviewed journal.

2.2.2. Exclusion criteria. Publications will be excluded if:

1. the sample size was fewer than 7 either in the CP group or the pain-free group;
2. three-dimensional coordinates of significant CTh results were not reported;
3. the studies only employed regions of interest analysis or global CTh analysis;
4. a direct pain-free compassion group was lacked;
5. the patient sample was overlapped with the other one with a larger sample size;
6. no baseline comparison was performed in case of a longitudinal study;
7. the pain duration was less than 3 months;
8. studies investigated experimental pain or acute pain;
9. the publications were conference abstracts, research protocols, case reports, letters, reviews, and editorials.

Figure 1 presents the flowchart of study selection following the PRISMA.

2.3. Data extraction

Data abstracted from the eligible studies will be: the first author’s name, year of publication, sample size, age, sex distribution, CP subtype, pain duration, pain intensity, magnetic resonance imaging (MRI) scanner manufacturer and platform, field strength, head coil, MRI sequence, repetition time (TR)/echo time (TE), voxel size, imaging processing software package, smooth kernel, statistical model, covariate, statistical threshold, peak coordinates, height of the peaks (t-values, z-values, or P-values), their stereotactic reference space (MNI or Talairach), and quality control.

2.4. Quality assessment

Quality assessment of each included study will be performed using a 12-point checklist based on a previous CTh meta-analysis (details in Table 1). The items utilized for the quality assessment were categorized into 3 parts: subjects (4 points), methods for imaging acquisition and analysis (5 points), and results and conclusions (3 points).

Two investigators will independently perform literature search, study selection, data extraction, and quality assessment. Any disagreements will be resolved by a consensus-based discussion.

2.5. Main coordinate-based meta-analysis (CBMA)

The SDM-PSI software package (version 6.21, https://www.sdmproject.com/) will be employed to conduct this main CBMA to identify consistent CTh differences between patients with CP and pain-free controls. The detailed processing steps can be found in the SDM-PSI reference manual (https://www.
To obtain the meta-analytic results, a correction for multiple comparison: threshold-free cluster enhancement family wise error rate (TFCE FWER) with a $P < .05$ and a minimum cluster size $\geq 10$ voxels, will be utilized.

2.6. Reliability analysis

Sensitivity analysis will be conducted to assess the stability of the results identified in the main CBMA. Heterogeneity analysis of significant results will be performed using the $I^2$ statistic. Publication bias will be examined using the Egger test. A threshold at $P < .05$ will be considered significant.

2.7. Subgroup analysis

Subgroup CBMA will be performed in clinical subtypes, different MRI field strengths (3.0T and 1.5T MRI), and different software packages for CTh analysis if the corresponding number of the datasets is sufficient ($n \geq 10$).

2.8. Meta-regression analysis

Meta-regression analyses will be carried out to examine if regional CTh alterations across studies were confounded by age, gender, pain duration, and pain intensity if they were available from at least 10 datasets. Threshold-free cluster enhancement family wise error rate (TFCE FWER) with a $P < .05$ and a minimum cluster size $\geq 10$ voxels will be employed to determine statistical significance.

2.9. Ethics and dissemination

Because we will use data from published studies, no Ethics approval or patient consent is required in this meta-analysis. We will publish the results of this meta-analysis in a peer-reviewed scientific journal.
Table 1
The checklist of quality assessment for the included cortical thickness studies.

12-point checklist

Category 1: Subjects
1. Patients were evaluated prospectively, specific diagnostic criteria were applied, and demographic data were reported.
2. Healthy comparison participants were evaluated prospectively; psychiatric and medical illnesses were excluded.
3. Important variables (e.g., age, gender, pain type, pain duration, pain intensity) were checked either via stratification or statistics.
4. Sample size per group: ≥ 20, scores 1; ≥ 7, scores 0.5

Category 2: Methods for image acquisition and analysis
5. Magnet strength: 3T, scores 1; 1.5T, scores 0.5
6. Quality control is performed.
7. The imaging technique used was clearly described so that it could be reproduced.
8. Whole brain cortical analysis was automated without a previously defined region.
9. Spatial coordinates were reported in a standard space (e.g., Talairach or MNI coordinates).

Category 3: Results and conclusions
10. Information about the covariates used, such as age and gender in the statistical model were provided.
11. Statistical results were corrected for multiple comparison scores 1, uncorrected scores 0.5.
12. Conclusions were consistent with the results obtained, and the limitations were discussed.

Total score

MNI=Montreal Neurological Institute.

3. Discussion

To the best of our knowledge, this will be the first CBMA of SBM studies that characterizes brain CTh alterations in CP. The reliability and reproducibility of the results from neuroimaging research have been increasingly concerned.[11] Many confounding factors, such as small sample size, variety in sample characters and etiologies, and differences in magnetic resonance imaging (MRI) scanner manufacturer and platform, field strength, imaging data acquisition parameter, imaging processing software package, smooth kernel, statistical model, covariate, and statistical threshold used, may cause the low reliability and reproducibility. Further investigations are necessary to reduce these impacts. This CBMA will provide quantitative evidence of common brain cortical morphometry of CP. The findings will help us to understand the neural basis underlying CP.

Author contributions

Conceptualization: HaiRong Ma, ZhenYu Dai, PingLei Pan
Data curation: HaiRong Ma, LiQin Sheng
Formal analysis: HaiRong Ma, LiQin Sheng
Funding acquisition: PingLei Pan
Investigation: HaiRong Ma, LiQin Sheng, Fei Chen
Methodology: LiQin Sheng, CongHu Yuan
Project administration: Fei Chen
Resources: LiQin Sheng, Fei Chen, CongHu Yuan
Software: LiQin Sheng
Supervision: ZhenYu Dai
Validation: Fei Chen, PingLei Pan
Visualization: LiQin Sheng, HaiRong Ma

Writing – original draft: HaiRong Ma
Writing – review & editing: ZhenYu Dai, PingLei Pan

References

[1] Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 2019;160:19–27.
[2] Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain 2015;156:1003–7.
[3] Fayaz A, Croft P, Langford RM, et al. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 2016;6:e013641:1-12.
[4] Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health 2011;11:770:1-5.
[5] Smallwood RF, Laird AR, Ramage AE, et al. Structural brain anomalies and chronic pain: a quantitative meta-analysis of gray matter volume. J Pain 2013;14:663–75.
[6] Cauda F, Palermo S, Costa T, et al. Gray matter alterations in chronic pain: a network-oriented meta-analytic approach. NeuroImage Clin 2014;4:676–86.
[7] Pan PL, Zhong JG, Shang HF, et al. Quantitative meta-analysis of grey matter anomalies in neuropathic pain. Eur J Pain 2015;19:1224–31.
[8] Shi H, Yuan C, Dai Z, et al. Gray matter abnormalities associated with fibromyalgia: a meta-analysis of voxel-based morphometric studies. Semin Arthritis Rheum 2016;46:330–7.
[9] Yuan C, Shi H, Pan P, et al. Gray matter abnormalities associated with chronic back pain: a meta-analysis of voxel-based morphometric studies. Clin J Pain 2017;33:983–90.
[10] Tatá K, Costa T, Nani A, et al. How do morphological alterations caused by chronic pain distribute across the brain? A meta-analytic co-alteration study. NeuroImage Clin 2018;18:815–30.
[11] Yin Y, He S, Xu J, et al. The neuro-patophysiology of temporoman-dibular disorders-related pain: a systematic review of structural and functional MRI studies. J Headache Pain 2020;21:78:1-20.
[12] Schmidt-Wilcke T. Neuroimaging of chronic pain. Best Pract Res Clin Rheumatol 2015;29:29–41.
[13] Malliet A, Coppériers I, Van Wilgen P, et al. Brain changes associated with cognitive and emotional factors in chronic pain: a systematic review. Eur J Pain 2017;21:769–86.
[14] Pfannmoller J, Lotze M. Review on biomarkers in the resting-state networks of chronic pain patients. Brain Cogn 2019;131:4–9.
[15] Zhao X, Xu M, Jorgensen K, et al. Neurochemical changes in patients with chronic low back pain detected by proton magnetic resonance spectroscopy: a systematic review. NeuroImage Clin 2017;13:33–8.
[16] Lesvin KJ, Drago T, Roman E, et al. Magnetic resonance spectroscopy across chronic pain disorders: a systematic review protocol synthesising anatomical and metabolite findings in chronic pain patients. Syst Rev 2019;8:338:1-7.
[17] Davis KD, Flor H, Greely HT, et al. Brain imaging tests for chronic pain: medical, legal and ethical issues and recommendations. Nat Rev Neurol 2017;13:624–38.
[18] Hutton C, Dragnaski B, Ashburner J, et al. A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. NeuroImage 2009;48:371–80.
[19] Lai KL, Niddam DM, Fuh JL, et al. Cortical morphological changes in chronic migraine in a Taiwanese cohort: surface- and voxel-based analyses. Cephalalgia 2020;40:575–85.
[20] Wolf RC, Hildebrandt V, Schmitgen MM, et al. Abarrent gray matter volume and cortical surface in paranoid-type delusional disorder. Neuropsychobiology 2020;79:335–44.
[21] Wu Y, Wu X, Wei Q, et al. Differences in cerebral structure associated with depressive symptoms in the elderly with Alzheimer’s disease. Front Aging Neurosci 2020;12:107:1-8.
[22] Lin C, Lee SH, Weng HH. Gray matter atrophy within the default mode network of fibromyalgia: a meta-analysis of voxel-based morphometry studies. Biomed Res Int 2016;2016:7296125:1-9.
[23] Tench CR, Tanasecu R, Constantinescu CS, et al. Coordinate based random effect size meta-analysis of neuroimaging studies. NeuroImage 2017;153:293–306.
[24] Albajes-Eizagirre A, Solanes A, Fullana MA, et al. Meta-analysis of voxel-based neuroimaging studies using seed-based d mapping with permutation of subject images (SDM-PSI). J Vis Exp 2019;27:153: e59941:1-7.
[25] Albajes-Eizagirre A, Solanes A, Vieta E, et al. Voxel-based meta-analysis via permutation of subject images (PSI): theory and implementation for SDM. Neuroimage 2019;186:174–84.

[26] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647:1-25.

[27] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097:1-6.

[28] Li Q, Zhao Y, Chen Z, et al. Meta-analysis of cortical thickness abnormalities in medication-free patients with major depressive disorder. Neuropsychopharmacology 2020;45:703–12.

[29] Dahlgren K, Ferris C, Hamann S. Neural correlates of successful emotional episodic encoding and retrieval: an SDM meta-analysis of neuroimaging studies. Neuropsychologia 2020;143:107495:1-19.

[30] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

[31] Nichols TE, Das S, Eickhoff SB, et al. Best practices in data analysis and sharing in neuroimaging using MRI. Nat Neurosci 2017;20:299–303.